The present invention provides a compound of Formula I:
wherein
R is hydrogen or methyl; and
Z is:
or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimer's disease.
本发明提供了一种式 I 的化合物:
其中
R 是氢或甲基;以及
Z 是
或其药学上可接受的盐,以及式 I 化合物用于治疗神经退行性疾病(如阿尔茨海默病)的用途。
6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds
申请人:Eli Lilly and Company
公开号:US10836773B1
公开(公告)日:2020-11-17
The present invention provides a compound of Formula I:
wherein
R is hydrogen or methyl; and
Z is:
or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimer's disease.
本发明提供了一种式 I 的化合物:
其中
R 是氢或甲基;以及
Z 是
或其药学上可接受的盐,以及式 I 化合物用于治疗神经退行性疾病(如阿尔茨海默病)的用途。
6-FLUORO-2-METHYLBENZO[D]THIAZOL-5-YL COMPOUNDS
申请人:Eli Lilly and Company
公开号:EP3856739A1
公开(公告)日:2021-08-04
[EN] 6-FLUORO-2-METHYLBENZO[D]THIAZOL-5-YL COMPOUNDS<br/>[FR] COMPOSÉS DE 6-FLUORO-2-MÉTHYLBENZO[D]THIAZOL-5-YL
申请人:LILLY CO ELI
公开号:WO2020068530A1
公开(公告)日:2020-04-02
The present invention provides a compound of Formula I: wherein R is hydrogen or methyl; and Z is:; or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimer's disease.
[EN] O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY<br/>[FR] POLYTHÉRAPIE PAR UN INHIBITEUR D'O-GLCNACASE (OGA)
申请人:[en]ELI LILLY AND COMPANY
公开号:WO2023070064A1
公开(公告)日:2023-04-27
The present invention provides methods of slowing progression of, treating, and/or preventing a disease characterized by amyloid beta deposits and/or a disease characterized by amyloid beta deposits and aberrant tau aggregation. Such methods comprise administering to a patient in need of such treatment an effective amount of an anti-N3pG Aβ antibody and an effective amount of an OGA inhibitor.